AUTHOR: LATOYA LANG
The Food and Drug Administration (FDA) has responded to MRA on our concerns regarding the confidentiality of marketing research data.
"FDA appreciates the concerns raised by MRA, and agrees with the importance of protecting the confidentiality of personal privacy information, including personally identifiable information, of those persons who participate in consumer surveys or other marketing research. Similarly, FDA understands the importance of protecting confidential commercial information, including trade secret and proprietary information."
MRA had contacted the FDA regarding the agency's sweeping demands for marketing research documents from Phillip Morris USA, Inc. to share our concerns about the need to keep respondents' personal information private and not jeopardize the research process or research trade secrets.
Read the FDA's response.
The big tax and budget reconciliation law, signed by President Trump on July 4, 2025, includes a pro...
June brought lots of sizzling policy developments for the insights industry -- some promising, other...
The Florida legislature turned its back on a bill opposed by the Insights Association that would hav...
Early in the second Trump Administration, the federal government instituted a uniform 15 percent cap...
The Consumer Financial Protection Bureau (CFPB) withdrew a regulatory proposal that could have unfai...
Legislative and regulatory issues facing the insights industry are blooming all over, including: a n...
0 Comments